Comparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity

Nese Saltoğlu, A Seza Inal, Yesim Tasova, Ozlem Kandemir, Nese Saltoğlu, A Seza Inal, Yesim Tasova, Ozlem Kandemir

Abstract

Background: Hepatitis B virus infection although preventable by vaccination remains an important health issue throughout the world due to its morbidity, mortality and economical losses. Early seroprotection is desirable for people at high risk of exposure. The aim of this study was to determine whether three-week hepatitis B vaccination (on days 0, 10 and 21) provide seroprotection or not.

Methods: The 120 subjects enrolled into the study were divided into two groups and vaccinated by the classic (months 0, 1, and 2) or the accelerated (days 0, 10, and 21) schedules and antibody response determined on days 30, 60, and 90 and, if below 10 mIU/ml(-1), again on day 180. For each individual in the classic group (B) three subjects were enrolled in the accelerated group (A). Recombinant hepatitis B vaccine (Gen-Hevac B, Pasteur) was given as 20 micrograms intramuscular injections via the deltoid muscle. A booster dose on day 365 was administered for each group. Family members of hepatitis B carriers and volunteer health personnel were enrolled into group A. To the B group only volunteers who wanted vaccination against hepatitis B were included.

Results: After three doses of vaccine, Anti-HBs titers reached protective levels in both groups. The number of vaccinees with seroprotective levels of Anti-HBs (> or =10 mIU/ml(-1)) on day 30 was 53 (58.9%) in group A and 9 (30.0%) in group B (p < 0.05). On day 60, there was no difference between group A and B, with response rates of 84.4% (n = 76) and 80.0% (n = 24) respectively (p > 0.05). On day 90 there was no difference between group B and group A; with 26 (86.7%) and 79 (87.7%) responders respectively. In both groups those with Anti-HBs levels <10 mIU/ml(-1) attained protective levels by day 180.

Conclusion: In this study, the three-week vaccination provided protective antibody titers within a shorter time compared to the classic schedule. Therefore, in order to provide rapid antibody production against hepatitis B virus, the accelerated vaccination schedule seems to be a good preference.

References

    1. Moradpur D, Wands JR. Understanding hepatitis B virus infection. N Engl J Med. 1995;332:1092–1093. doi: 10.1056/NEJM199504203321610.
    1. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadowski R, Morrison JM, Kellner A. Hepatitis B vaccine. N Engl J Med. 1980;303:833–41.
    1. Hollinger FB. Factors influencing the immune response to hepatitis vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med. 1989;87:36S–40S.
    1. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;332:196–204. doi: 10.1056/NEJM199701163360307.
    1. Orsolini P, Belloni C, Klersy C, Campisi D, Chirico G, Togni C, Maccarini U, Polatti F, Martinetti M, Salvaneschi L, et al. Anti-HBV neonatal immunization with recombinant vaccine. Part I. Critical appraisal for a long-lived antibody course. Vaccine. 1995;13:551–4. doi: 10.1016/0264-410X(94)00043-M.
    1. Goldfarb J, Baley J, Medendorp SV, Seto D, Garcia H, Toy P, Watson B, Gooch MW, 3, Krause D. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J. 1994;13:18–22.
    1. Wahl M, Hermodsson S, Iwarson S. Hepatitis B vaccination with short dose intervals – a possible alternative for post-exposure prophylaxis? Infection. 1988;16:229–32.
    1. Wilkinson SE, Morath M, Bennett DL, Burgess MA, Isaacs D. Accelerated schedule of hepatitis B vaccination in high-risk youth. J Paediatr Child Health. 1996;32:60–2.
    1. Belloni C, Pistorio A, Tinelli C, Komakec J, Chirico G, Rovelli D, Gulminetti R, Commolli G, Orsolini P, Rondini G. Early immunisation with hepatitis B vaccine: a five-year study. Vaccine. 2000;18:1307–1311. doi: 10.1016/S0264-410X(99)00414-4.
    1. Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med. 1997;103:217–22. doi: 10.1016/S0002-9343(97)00132-0.
    1. Santagostino E, Mannucci PM, Gringeri A, Rumi MG, Rafanelli D, Rocino A, Schiavoni M, Chistolini A, Di Bona E, Muleo G. Accelerated schedule of hepatitis B vaccination in patients with hemophilia. J Med Virol. 1993;41:95–8.
    1. Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc. 1998;30:797–9. doi: 10.1016/S0041-1345(98)00053-0.
    1. Engler SH, Sauer PW, Golling M, Klar EA, enz C, Stremmel W, Kallinowski B. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol. 2001;13:363–7. doi: 10.1097/00042737-200104000-00010.
    1. Marchou B, Picot N, Chavanet P, Auvergnat JC, Armengaud M, Devilliers P, Cerisier JE, Marie FN, Excler JL. Three-week hepatitis B vaccination provides protective immunity. Vaccine. 1993;11:1383–5. doi: 10.1016/0264-410X(93)90165-T.
    1. Kaya A, Erol S, Taşyaran MA, Aktaş O, Yılmaz Ş. Early antibody response of 3-weeks hepatitis B vaccination schedule. J of Turkish Med. 1997;2:1–4.
    1. Harries AD, Clark M, Beeching NJ, Lavelle J, Mutton KJ. Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J Infect. 1991;23:251–4.
    1. Iwarson S, Wahl M, Ruttimann E, Snoy P, Seto B, Geretty RJ. Successful postexposure vaccination against hepatitis B in chimpanzees. J Med Virol. 1988;25:433–9.
    1. Marchou B, Excler JL, Bourderioux C, Salaun J, Picot N, Yvonnet B, Cerisier JE, Salamon H, Auvergnat JC. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: A multicenter, randomized trial comparing accelerated and classic vaccination schedules. Clin Infect Dis. 1995;172:258–60.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever